Parkinsons disease

Reading File

Finding Sources

Searching PubMed

"Parkinson disease"[MeSH Terms] AND management

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

I now have comprehensive material. Let me compile the full, authoritative response on Parkinson's Disease.

Parkinson's Disease

Overview

Parkinson's disease (PD) is a progressive neurodegenerative disorder and the second most common neurodegenerative disease after Alzheimer's. Symptoms typically emerge between 55 and 65 years of age. It was first formally described by James Parkinson in 1817 as the "shaking palsy." - Bradley and Daroff's Neurology in Clinical Practice

Pathophysiology

The hallmark pathology involves degeneration of pigmented dopaminergic neurons in the substantia nigra pars compacta. By the time motor symptoms appear, approximately 60-80% of these neurons have already been lost.

The Dopamine-Acetylcholine Imbalance

Normally, the neostriatum maintains a balance between:

Inhibitory dopaminergic neurons (from substantia nigra)
Excitatory cholinergic neurons (within neostriatum)

In PD, destruction of substantia nigra cells depletes dopamine in the neostriatum. The loss of dopamine's inhibitory influence allows cholinergic neurons to become relatively overactive, triggering a chain of abnormal signaling leading to motor dysfunction.

Role of substantia nigra in Parkinson disease - dopamine/acetylcholine imbalance

Figure: Role of the substantia nigra in PD. Cell death causes less dopamine release in the neostriatum, leading to unchecked ACh activity and impaired mobility. - Lippincott Illustrated Reviews: Pharmacology

Basal Ganglia Circuit Disruption

Dopamine acts on two opposing pathways in the striatum:

Direct pathway (D1 receptors): dopamine is excitatory - facilitates movement
Indirect pathway (D2 receptors): dopamine is inhibitory - reduces the brake on movement

In PD, dopamine loss reduces excitation via the direct pathway AND reduces inhibition via the indirect pathway - both effects converge to produce excessive inhibition of the thalamus, resulting in the hypokinetic features of PD. - Costanzo Physiology 7e

Alpha-Synuclein and Lewy Bodies

The pathological hallmark on histology is the Lewy body - an intracytoplasmic inclusion with a dense eosinophilic core and a lighter halo, found within surviving dopaminergic neurons. Lewy bodies and Lewy neurites result from abnormal aggregation of alpha-synuclein protein. They may also contain neurofilaments, parkin, and ubiquitin.

Lewy bodies and Lewy neurites - alpha-synuclein aggregates

Figure: Lewy bodies (intracellular) and Lewy neurites (in neuronal processes) - both composed of aggregated alpha-synuclein. - Stahl's Essential Psychopharmacology

Neuronal loss is not confined to the substantia nigra - it also occurs in the locus coeruleus, raphe nuclei, dorsal motor nucleus of the vagus, olfactory bulb, and enteric nervous system.

Clinical Features

Motor Symptoms (the classic tetrad)

Feature	Description
Resting tremor	"Pill-rolling" tremor at 4-6 Hz, suppressed by voluntary movement
Rigidity	Increased tone throughout range of motion; often "cogwheel" type
Bradykinesia	Slowness of voluntary movement; most disabling feature
Postural instability	Impaired reflex adjustments; late feature, leads to falls

Other Motor Manifestations

Masked facies (hypomimia) - reduced facial expression, decreased blink rate
Micrographia - progressively smaller handwriting
Hypophonia - soft, monotone voice with hurried muttering quality
Festinating gait - small, shuffling steps; difficulty initiating (freezing), tendency to lean forward (anteropulsion) or backward (retropulsion)
En bloc turning - turning without normal torso twist
Myerson's sign - inability to suppress blinking when glabella is repeatedly tapped (non-specific)
Dysphagia - recognized by Parkinson himself in 1817; subjective prevalence ~35%, objective up to 82%; involves oral, pharyngeal, and esophageal phases; silent aspiration in 15-33%

Non-Motor Symptoms (often precede motor symptoms)

Autonomic: orthostatic hypotension, constipation, urinary urgency, sexual dysfunction, seborrhea
Sleep: REM sleep behavior disorder (RBD) - often an early prodromal marker
Olfactory: hyposmia/anosmia (may predate motor symptoms by years)
Neuropsychiatric: depression (most common psychiatric disturbance), anxiety, apathy, psychosis (typically medication-induced visual hallucinations in ~40%, delusions in ~16%)
Cognitive: mild executive dysfunction is common early; dementia occurs in 15-40% later in the course

Note on psychosis: In PD, hallucinations are usually fleeting and nocturnal, motor symptoms virtually always precede psychosis, and psychosis is generally medication-induced. This distinguishes it from Dementia with Lewy Bodies (DLB), where psychosis is a core feature occurring even without medications. - Bradley and Daroff's Neurology in Clinical Practice

Diagnosis

PD is a clinical diagnosis based on the presence of bradykinesia plus at least one of: resting tremor or rigidity. There is no definitive antemortem biological test.

Supporting features:

Asymmetric onset
Good response to levodopa
Progressive course over 5-15 years

Investigations:

DaT SPECT (dopamine transporter scan): shows reduced uptake in the striatum; useful when diagnosis is uncertain
MRI brain: typically normal in idiopathic PD; used to exclude structural causes

Red flags suggesting alternative diagnoses:

Early postural instability (before 3 years)
Rapid progression
Symmetrical onset
No response to levodopa
Early falls, early dementia, early autonomic failure, supranuclear gaze palsy, cerebellar signs

Up to 30% of PD patients never develop tremor, so its absence does not exclude the diagnosis. - Neuroanatomy Through Clinical Cases, 3e

Pharmacological Treatment

Drug therapy aims to restore the dopamine/acetylcholine balance in the basal ganglia. Currently available drugs offer only symptomatic relief - none have proven neuroprotective or disease-modifying effects.

1. Levodopa + Carbidopa (first-line, most effective)

Levodopa is the metabolic precursor of dopamine. It crosses the blood-brain barrier and is converted to dopamine by surviving substantia nigra neurons.

Carbidopa is a peripheral dopa-decarboxylase inhibitor that:

Reduces peripheral conversion of levodopa to dopamine (preventing nausea, vomiting, cardiac arrhythmias)
Increases CNS availability of levodopa
Allows a 75% reduction in levodopa dose

Problems with long-term levodopa use:

Wearing-off phenomenon: as neuronal loss progresses, the drug effect duration shortens between doses
On-off fluctuations: unpredictable swings between mobile ("on") and immobile ("off") states
Dyskinesias: involuntary choreiform movements, typically at peak dose
Nausea, orthostatic hypotension, psychosis

2. COMT Inhibitors (adjunct to levodopa)

Entacapone, opicapone, tolcapone inhibit catechol-O-methyltransferase, which normally converts levodopa to 3-O-methyldopa (a metabolite that competes with levodopa for CNS transport). By blocking this pathway, COMT inhibitors:

Increase central levodopa uptake
Raise brain dopamine levels
Reduce "wearing-off" effects

Tolcapone carries a risk of fulminant hepatic necrosis and is reserved for cases where other agents have failed. Entacapone and opicapone are preferred and lack this hepatotoxicity. - Lippincott Illustrated Reviews: Pharmacology

3. MAO-B Inhibitors

Selegiline and rasagiline selectively inhibit MAO type B, which is the primary enzyme for dopamine catabolism in the brain. This prolongs dopamine availability. They may be used as initial monotherapy in mild disease or as adjuncts to levodopa.

4. Dopamine Receptor Agonists

Non-ergot agents (preferred): ropinirole, pramipexole, rotigotine, apomorphine Ergot derivative (less used): bromocriptine

These agents directly stimulate dopamine receptors. Advantages over levodopa:

Longer duration of action
Lower risk of dyskinesia
Useful in patients with levodopa fluctuations
Initial monotherapy in younger patients delays dyskinesia

Adverse effects: nausea, orthostatic hypotension, somnolence, hallucinations, impulse control disorders (gambling, hypersexuality - particularly with pramipexole/ropinirole).

5. Anticholinergic Agents

Benztropine, trihexyphenidyl - reduce cholinergic overactivity. Primarily useful for tremor in younger patients. Cause significant anticholinergic side effects (confusion, memory impairment, urinary retention) and are generally avoided in the elderly.

6. Amantadine

An NMDA receptor antagonist with mild dopaminergic and anticholinergic properties. Used for mild early symptoms and, importantly, for reducing levodopa-induced dyskinesias in advanced disease.

Non-Pharmacological and Surgical Treatment

Exercise and Physiotherapy

A 2025 network meta-analysis (PMID: 39880702) found that specific exercise types and doses improve motor symptoms in PD. Resistance training, treadmill training, and dance therapy have shown benefits for gait, balance, and bradykinesia.

Deep Brain Stimulation (DBS)

The most effective surgical option. Electrodes are implanted in the subthalamic nucleus (STN) or globus pallidus interna (GPi). DBS is indicated for:

Advanced PD with motor fluctuations refractory to medical therapy
Intolerable levodopa-induced dyskinesias
Preserved cognitive function

DBS continuously modulates the cortico-striato-thalamo-cortical circuit, reducing pathological beta oscillations and restoring more physiological motor cortex excitability. The effect on tremor, rigidity, and bradykinesia may accumulate over hours of stimulation. - Bradley and Daroff's Neurology in Clinical Practice

Repetitive Transcranial Magnetic Stimulation (rTMS)

Investigational. Rationale is to increase motor cortex excitability and suppress pathological beta oscillations. Results of class 1 trials remain ambiguous. Larger RCTs are needed.

Swallowing and Speech Therapy

Given that dysphagia affects up to 82% objectively and silent aspiration occurs in 15-33%, speech and language therapy is an important component. Aspiration pneumonia is a leading cause of death in advanced PD. REM sleep behavior disorder management and fall prevention are also key non-pharmacological targets.

Complications and Prognosis

Disease progression is typically insidious, over 5-15 years
Many patients die of other causes (given late onset) rather than directly from PD
Leading causes of death in advanced PD: aspiration pneumonia, falls/trauma, immobility complications
Dementia (PD dementia) occurs in 15-40% of patients late in the course
PD dementia shares pathological overlap with DLB (both are "synucleinopathies")

Key Differential Diagnoses

Condition	Distinguishing Features
Drug-induced parkinsonism	History of dopamine blockers (antipsychotics, metoclopramide); usually reversible
Multiple System Atrophy (MSA)	Early autonomic failure, cerebellar signs, poor levodopa response
Progressive Supranuclear Palsy (PSP)	Early postural instability, supranuclear gaze palsy, axial rigidity
Corticobasal Degeneration (CBD)	Alien limb, asymmetric apraxia, cortical sensory loss
Dementia with Lewy Bodies (DLB)	Dementia precedes or co-occurs with parkinsonism, fluctuating cognition, spontaneous psychosis
Essential Tremor	Action/postural tremor, no bradykinesia or rigidity, family history

Recent Evidence (2024-2026)

Exercise for motor symptoms (PMID: 39880702, 2025 network meta-analysis): Specific exercise modalities significantly improve motor outcomes - exercise should be considered a core therapeutic component, not optional.
Virtual reality for balance (PMID: 40142335, 2025 meta-analysis): VR combined with conventional therapy improves balance compared to conventional therapy alone.
Anxiety management (PMID: 40568748, 2025): Anxiety affects up to 50% of PD patients and remains undertreated; a recent meta-analysis reviewed pharmacological and non-pharmacological approaches.

Pls provide me Harrison based for sure

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have all the content I need from Harrison's 22e. Let me compile the comprehensive Harrison-based answer.

Parkinson's Disease

Harrison's Principles of Internal Medicine, 22nd Edition (2025)

Authors: C. Warren Olanow, Anthony H.V. Schapira, Christine Klein

Epidemiology

PD is the second most common age-related neurodegenerative disease, exceeded only by Alzheimer's disease. Key epidemiological facts from Harrison's:

Estimated ~10.8 million people with PD worldwide; expected to double within 20 years due to population aging
Mean age of onset: ~60 years (but can occur in the 20s, especially with pathogenic gene mutations)
Lifetime risk: ~3% for men, ~2% for women
Frequency increases steeply with age

Pathology

The hallmark pathological features of PD are:

Degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc)
Reduced striatal dopamine
Lewy pathology - intraneuronal proteinaceous inclusions (Lewy bodies in cell bodies; Lewy neurites in axons) that stain positive for alpha-synuclein (Fig. 446-1)

Neurodegeneration is not limited to the SNc. Lewy pathology also affects:

Cholinergic neurons of the nucleus basalis of Meynert (NBM)
Norepinephrine neurons of the locus coeruleus (LC)
Serotonin neurons of raphe nuclei
Neurons of the olfactory system, cerebral hemispheres, spinal cord, and peripheral autonomic nervous system

This widespread pathology explains the many non-motor features of PD.

Premotor Stage ("Body-First vs. Brain-First" PD)

Harrison's 22e highlights a key recent concept: clinical symptoms reflecting early nondopaminergic involvement - constipation, anosmia, REM sleep behavior disorder (RBD), and cardiac denervation - can precede the onset of classic motor features by several years to decades. These are now considered to represent an early premotor form of the disease, not merely risk factors. Two new biological classification systems have been developed:

Based on neuronal alpha-synuclein accumulation staging
Based on alpha-synuclein deposition + distribution of neurodegeneration + pathogenic gene variants

Etiology and Pathogenesis

Genetics

Gene	Inheritance	Notes
SNCA (alpha-synuclein)	Autosomal dominant	Point mutations and duplications/triplications; multiplications increase expression and severity
LRRK2 (leucine-rich repeat kinase 2)	Autosomal dominant	p.G2019S is the most common mutation; founder effect in Ashkenazi Jewish and North African Berber populations
PRKN (Parkin)	Autosomal recessive	Most common AR cause; early-onset PD (median AAO ~32 years)
PINK1	Autosomal recessive	Mitochondrial kinase; early-onset
PARK7 (DJ-1)	Autosomal recessive	Rare; early-onset
GBA1 (glucocerebrosidase)	Risk factor	Heterozygous mutations are the most common genetic risk factor for PD

Alpha-synuclein prion hypothesis: Based on experimental evidence (injection of PD brain homogenates triggers spread of pathology in mice; Lewy pathology develops in fetal nigral cell grafts transplanted into PD patients), Harrison's describes the hypothesis that alpha-synuclein may behave like a prion - misfolded protein that self-propagates and spreads from cell to cell in a stereotyped pattern (Braak staging).

Putative Mechanisms of Cell Death

Oxidative stress (increased free radicals from dopamine metabolism)
Mitochondrial dysfunction (Complex I deficiency in SNc)
Proteasomal/lysosomal dysfunction - failure to clear alpha-synuclein aggregates
Neuroinflammation - activated microglia in SNc
Apoptosis as a final common pathway

MPTP Model

A key insight came from drug abusers who developed acute parkinsonism after exposure to MPTP (a contaminant of synthetic heroin). MPTP is converted by MAO-B to MPP+, which selectively damages dopamine neurons by inhibiting mitochondrial Complex I. This model validates the role of mitochondrial dysfunction and provided the rationale for MAO-B inhibitors as potential neuroprotective agents.

Clinical Features

Cardinal Motor Features (TABLE 446-1)

Cardinal Features	Other Motor Features	Nonmotor Features
Bradykinesia	Micrographia	Anosmia
Rest tremor	Masked facies (hypomimia)	Sensory disturbances (pain, hyposmia)
Rigidity	Reduced eye blinking	Mood disorders (depression, anxiety, apathy)
Postural instability	Drooling	Sleep disturbances (fragmented sleep, RBD)
	Hypophonia	Autonomic disturbances
	Dysphagia	Orthostatic hypotension
	Freezing of gait	GI disturbances
	Falling	Genitourinary disturbances
		Cognitive impairment/dementia
		Psychosis (hallucinations, delusions)

Diagnosis - UK Brain Bank Criteria & MDS Criteria

Historically, PD was diagnosed based on 2 of 3 parkinsonian features (tremor, rigidity, bradykinesia). However, postmortem studies found a 24% error rate with these criteria alone.

The UK Brain Bank Criteria - combining bradykinesia + rigidity + rest tremor + asymmetry + good levodopa response - improved pathological confirmation to >90% of cases.

The newer MDS Clinical Diagnostic Criteria (Movement Disorder Society) retain motor parkinsonism as the core feature and add:

Supportive criteria (features increasing diagnostic confidence)
Absolute exclusion criteria
Red flags (must be counterbalanced by supportive criteria)

Two diagnostic certainty levels: Clinically Established PD and Clinically Probable PD.

Imaging

DaT PET/SPECT: Shows reduced and asymmetric uptake in the striatum, particularly in the posterior putamen with relative sparing of the caudate nucleus (Fig. 446-3). This reflects degeneration of dopaminergic nerve terminals projecting from the SNc.

In atypical parkinsonism (MSA, PSP): striatal dopamine depletion can also be seen, so DaT imaging does NOT reliably distinguish PD from atypical parkinsonism. However, FDG-PET of basal ganglia/thalamic network may help - PD shows decreased GPI activity with increased thalamic activity (opposite in atypical parkinsonism).

Differential Diagnosis

Atypical Parkinsonism (TABLE 446-3 from Harrison's)

Features suggesting atypical or secondary parkinsonism:

Symptom/Sign	Alternative Diagnosis
Early speech and gait impairment, no tremor, no asymmetry, early falls	Atypical parkinsonism (MSA, PSP)
Neuroleptic/metoclopramide exposure	Drug-induced parkinsonism
Onset before age 40	Genetic PD, Wilson's disease, DRD
Liver disease	Wilson's disease
Dementia/hallucinations preceding motor features	Dementia with Lewy Bodies (DLB)
Diplopia, impaired vertical (downward) gaze	PSP
Poor or no response to adequate levodopa trial	Atypical or secondary parkinsonism

MSA (Multiple System Atrophy): Parkinsonism + cerebellar signs + prominent autonomic dysfunction; alpha-synuclein accumulates in oligodendrocytes (GCIs), not neurons; MRI shows putaminal rim, hot cross bun sign.

PSP (Progressive Supranuclear Palsy): Parkinsonism + slow saccades + restricted downward gaze + early falls (hyperextension of neck); tau pathology (neurofibrillary tangles); hummingbird sign on MRI.

Drug-induced parkinsonism: Harrison's specifically flags metoclopramide - physicians must be aware that drugs used for GI problems are neuroleptics and can cause secondary parkinsonism.

Dopa-Responsive Dystonia (DRD): Especially in those <20 years with parkinsonism; GTP-cyclohydrolase 1 mutation; responds to levodopa but no degeneration on FD-PET and no drug-induced dyskinesias.

Wilson's disease must always be ruled out in young-onset parkinsonism, as progression can be prevented with copper chelators.

Treatment

LEVODOPA - The Gold Standard

"Levodopa remains the most effective symptomatic treatment for PD and the gold standard against which new therapies are compared." - Harrison's 22e

Historical background: Carlsson (late 1950s) showed reserpine-induced parkinsonism in rabbits was reversed by levodopa. Hornykiewicz demonstrated striatal dopamine deficiency in PD patients, suggesting dopamine replacement therapy.

Mechanism: Levodopa crosses the BBB (dopamine cannot); it is converted to dopamine in surviving SNc neurons, restoring striatal dopamine.

Peripheral decarboxylase inhibitors are always co-administered:

Carbidopa (USA - Sinemet)
Benserazide (most other countries - Madopar)
Prevent peripheral levodopa conversion to dopamine, reducing: nausea, vomiting, orthostatic hypotension (mediated via area postrema dopamine receptors outside the BBB)

Available formulations (Harrison's 22e - updated list):

Standard oral levodopa/carbidopa (Sinemet)
Controlled-release (Sinemet CR / Madopar HP)
Long-acting oral formulation (Rytary)
Levodopa/carbidopa/entacapone combined (Stalevo)
Levodopa-carbidopa intestinal gel - continuous intra-intestinal infusion
Continuous subcutaneous infusions of levodopa
Inhaled levodopa - absorbed through pulmonary alveoli (approved on-demand therapy for off periods)

Motor Complications of Levodopa (Fig. 446-6)

With ongoing disease progression and chronic levodopa use, most patients develop motor complications:

Wearing-off phenomenon: Duration of benefit per dose progressively shortens. Initially, benefit lasts many hours (the "long-duration response"). Eventually, benefit approaches the drug's half-life (60-90 min).
On-off phenomenon: Rapid, unpredictable switches between the "on" state (drug working) and "off" state (parkinsonism returns).
Dyskinesias: Involuntary choreiform/dystonic movements, typically at peak dose during "on" periods.

In advanced cases, the response to an individual dose may be variable and unpredictable - full-on, partial-on, delayed, or even dose failure.

On-demand therapies for off periods (3 FDA-approved):

Inhaled levodopa (Inbrija)
Subcutaneous apomorphine injection (Apokyn)
Sublingual apomorphine (Kynmobi)

All are fast-acting, avoid variable oral bioavailability, and provide predictable return to the on state.

Other Pharmacological Agents

Drug Class	Examples	Role
MAO-B inhibitors	Selegiline, rasagiline	Early monotherapy or adjunct; potential neuroprotective effect (ADAGIO trial - rasagiline 1 mg/d showed disease-modifying consistent results)
Dopamine agonists	Pramipexole, ropinirole, rotigotine, apomorphine	Monotherapy in early disease (especially younger patients); adjunct in fluctuating disease; longer duration than levodopa; lower dyskinesia risk
COMT inhibitors	Entacapone, opicapone, tolcapone	Reduce wearing-off; tolcapone reserved for refractory cases (hepatotoxicity risk)
Amantadine	NMDA antagonist	Mild early PD; importantly, reduces levodopa-induced dyskinesias
Anticholinergics	Benztropine, trihexyphenidyl	Primarily for tremor in younger patients; avoid in elderly

Neuroprotection - The Major Unmet Need

"A neuroprotective or disease-modifying therapy that slows or stops disease progression remains the major unmet therapeutic need." - Harrison's 22e

Current investigational targets:

Agents preventing toxic alpha-synuclein species formation or accumulation
LRRK2 inhibitors
GCase (GBA1) enhancers
GLP-1 agonists (developed for diabetes; anti-inflammatory and pro-mitochondrial effects; results in double-blind trials have been inconsistent)

The DATATOP study showed selegiline delayed disability requiring levodopa introduction, but could not definitively prove neuroprotection vs. symptomatic masking. The ADAGIO study using a delayed-start design showed rasagiline 1 mg/d had benefits consistent with a disease-modifying effect, but the 2 mg dose failed - reason remains uncertain.

Surgical Treatment

History: Early surgery involved motor cortex lesions (improved tremor but caused motor deficits - abandoned). Then VIM thalamotomy was found to reduce contralateral tremor without motor deficits, but had no effect on bradykinesia or rigidity.

Deep Brain Stimulation (DBS) - current standard surgical approach:

Primary targets: subthalamic nucleus (STN) or globus pallidus interna (GPi)
STN-DBS: reduces all cardinal motor features; often allows levodopa dose reduction
GPi-DBS: particularly effective for dyskinesias
Indications: Advanced PD with motor fluctuations refractory to optimized medical therapy; intolerable dyskinesias; preserved cognitive function
Contraindications/poor candidates: Significant dementia, prominent non-dopaminergic features (freezing, falls), active psychiatric illness, unrealistic expectations
Focused ultrasound thalamotomy (non-invasive): now available as an alternative for tremor-predominant PD

Emerging / Experimental Therapies (Harrison's 22e)

Cell-based/Stem Cell Therapies: Two NIH-sponsored trials of fetal midbrain cell grafts in the 1990s failed - only a small subset of younger patients showed benefit, and some developed graft-induced dyskinesias (attributed to serotonergic neurons inadvertently included in grafts). A newer European trial was terminated due to slow enrollment and insufficient cell harvest. Current excitement centers on iPSC-derived dopamine neurons and embryonic stem cell-derived neurons:

Japan (Kyoto University): Phase 1/2 trial since 2018; 7 patients treated
USA: FDA approved first clinical trial of ESC-derived dopamine neurons; 10 patients in Phase 1
Europe: Trial of ESC-derived neurons began 2023; 4 patients on low dose with no acute adverse effects

Non-Motor Management

Harrison's emphasizes that nondopaminergic features (especially falls and dementia) are the primary source of disability and main reason for hospitalization and nursing home placement in the levodopa era - not motor symptoms.

Key non-motor domains:

Depression: Most common psychiatric disturbance; SSRIs are first-line (though may worsen motor symptoms); tricyclics as alternative
Psychosis: Visual hallucinations in up to 40% - usually medication-induced; clozapine (low dose) or pimavanserin (5-HT2A inverse agonist, does not worsen parkinsonism) are options
Dementia: 15-40% develop dementia; rivastigmine (ChEI) has some evidence
Autonomic: Orthostatic hypotension (fludrocortisone, midodrine, droxidopa); constipation; urinary dysfunction
Sleep/RBD: Melatonin or low-dose clonazepam for RBD
Anosmia: No treatment; important as a premotor marker

Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025) - Chapter 446: Parkinson's Disease and Related Disorders. Authors: C. Warren Olanow, Anthony H.V. Schapira, Christine Klein.

This is not much to write in pg exam

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Here is the full PG exam-format answer, entirely from Harrison's 22e (Chapter 446):

PARKINSON'S DISEASE

Harrison's Principles of Internal Medicine, 22nd Edition — Chapter 446

C. Warren Olanow | Anthony H.V. Schapira | Christine Klein

1. DEFINITION & EPIDEMIOLOGY

2nd most common age-related neurodegenerative disease (after Alzheimer's)
First described by James Parkinson in 1817 as "shaking palsy"
Prevalence: ~10.8 million worldwide; expected to double in 20 years
Mean age of onset: ~60 years; can occur in 20s with gene mutations
Lifetime risk: 3% men, 2% women
~15% of cases are familial; the rest are sporadic

2. PATHOLOGY (FIGURE 446-1 - Harrison's)

Gross pathology

FIGURE 446-1A: PD brain (right) showing pallor/depigmentation of SNc vs. normal control (left) - loss of melanized dopamine neurons

FIGURE 446-1A: Cross-section of PD midbrain (right) vs. normal (left) - note the striking pallor/depigmentation of the substantia nigra pars compacta due to loss of melanized dopaminergic neurons.

Microscopic pathology

FIGURE 446-1C: Lewy bodies (arrows) - eosinophilic intracytoplasmic inclusions within melanized dopamine neurons of the substantia nigra

FIGURE 446-1C: Lewy bodies (arrows) — eosinophilic intracytoplasmic inclusions with a dense core and pale halo, within melanized dopamine neurons of the SNc.

Three hallmark pathological features:

Degeneration of dopaminergic neurons in the SNc (substantia nigra pars compacta)
Reduced striatal dopamine
Lewy pathology — intraneuronal alpha-synuclein aggregates as:
- Lewy bodies (in cell bodies)
- Lewy neurites (in axons)

Nondopaminergic involvement (explains nonmotor features):

Lewy pathology also affects:

Cholinergic neurons of nucleus basalis of Meynert (NBM) → dementia, cognitive dysfunction
Norepinephrine neurons of locus coeruleus (LC) → depression, sleep
Serotonin neurons of raphe nuclei → mood disorders
Olfactory system → anosmia
Dorsal motor nucleus of vagus → autonomic dysfunction
Peripheral autonomic nervous system, GI tract → constipation, gastroparesis
Spinal cord and cerebral hemispheres

3. ETIOLOGY AND PATHOGENESIS

A. Genetics (TABLE 446-4 — Harrison's)

Gene	Inheritance	Key Features
SNCA (alpha-synuclein)	AD	Median AAO 46 yrs; duplications cause classical PD; triplications cause severe, early-onset PD with dementia. Alpha-syn = major component of Lewy bodies
LRRK2	AD	Most common known genetic form. Median AAO 56 yrs; clinically typical PD; slightly slower progression. p.G2019S mutation most common — founder effect in Ashkenazi Jewish and North African Berber populations
VPS35	AD	Median AAO 52 yrs; clinically typical PD; very rare
GBA1	Risk factor	Heterozygous variants = most common genetic risk factor; faster progression + greater cognitive risk
PRKN (Parkin)	AR	Most common AR cause; early-onset PD (median AAO 32 yrs, range 9-67 yrs)
PINK1	AR	Mitochondrial kinase; early-onset
PARK7 (DJ-1)	AR	Very rare; early-onset

"Double-hit" hypothesis (Harrison's 22e): Many PD cases may result from (1) genetic susceptibility factor + (2) toxic environmental exposure. Neither alone is sufficient.

Important genetic concept: Duplication/triplication of wild-type SNCA alone causes PD - meaning increased production of the normal protein is sufficient to cause disease.

Alpha-synuclein as a prion: Lewy pathology was found in healthy embryonic dopamine neurons transplanted into PD patients - implying the abnormal protein transferred from diseased to healthy cells. This suggests PD may be a prion-like disorder.

B. Environmental Factors

MPTP (methyl-phenyl-tetrahydropyridine) — contaminant of illicit synthetic heroin; caused acute PD syndrome in California addicts in 1980s
- MPTP → oxidized (by MAO-B) to MPP+ → mitochondrial Complex I inhibitor → selective dopamine neuron death
- Importantly: MPTP/MPTP-like compounds have NOT been linked to sporadic PD
Risk factors (inconsistent evidence): pesticides, rural living, farming, well water, solvents
Possible protective factors: caffeine, cigarette smoking, NSAIDs, calcium channel blockers

C. Pathogenetic Mechanisms

Oxidative stress — free radical production from dopamine metabolism
Mitochondrial dysfunction — Complex I deficiency in SNc
Proteasomal/lysosomal failure — impaired clearance of alpha-synuclein aggregates
Neuroinflammation — activated microglia in SNc
Apoptosis — final common pathway

D. Braak Staging (Alpha-synuclein spread)

Lewy pathology begins in the olfactory system, GI tract, and dorsal vagal nucleus and spreads in a predictable, sequential (caudal-to-rostral) manner to reach the SNc (mid-stage) and then the cerebral hemispheres (late stage). This explains why:

Anosmia, constipation, RBD precede motor symptoms by years to decades
These are now classified as premotor PD, not just risk factors
Concept of "body-first" vs "brain-first" PD based on where pathology initiates

4. CLINICAL FEATURES (TABLE 446-1 — Harrison's)

A. Cardinal Motor Features (TRAP)

Feature	Details
Tremor (rest)	"Pill-rolling"; 4-6 Hz; suppressed by voluntary movement; asymmetric onset
Rigidity	Cogwheel or lead-pipe; throughout range of motion
Akinesia/Bradykinesia	Slowing of movement; the most disabling feature
Postural instability	Impaired postural reflexes; late feature; major cause of falls

B. Other Motor Features

Micrographia — progressively smaller handwriting
Masked facies (hypomimia) — reduced facial expression
Reduced eye blinking
Drooling (sialorrhoea)
Hypophonia — soft, monotone voice
Dysphagia — oral, pharyngeal, esophageal
Freezing of gait — sudden arrest of movement ("feet glued to the ground"); major cause of falls; may respond to sensory cues (marching, stepping over imaginary line, singing)
Festinating gait — small, shuffling, rapid steps; anteropulsion; reduced arm swing; en bloc turning
Retropulsion — backward stepping on pull test

C. Non-Motor Features

System	Features
Autonomic	Orthostatic hypotension, constipation, urinary urgency, sexual dysfunction, seborrhea, sialorrhoea
Sleep	REM sleep behaviour disorder (RBD) — often premotor; fragmented sleep; excess daytime sleepiness
Sensory	Anosmia/hyposmia (early premotor), pain, restless legs
Mood	Depression (~50% of PD patients), anxiety, apathy, panic attacks
Cognitive	Mild executive dysfunction early; dementia in up to 80% ultimately — primarily affects executive function and attention; relative sparing of language, memory, calculation
Psychosis	Visual hallucinations (typically formed, nonthreatening); often medication-induced

5. DIAGNOSIS

Clinical Criteria

Historically: 2 of 3 features (tremor, rigidity, bradykinesia) → 24% error rate at autopsy

UK Brain Bank Criteria (>90% pathological accuracy):

Core: Bradykinesia + rigidity
Plus: rest tremor, asymmetry of onset, good response to levodopa

MDS Clinical Diagnostic Criteria (most current - Harrison's 22e):

Core: Motor parkinsonism (bradykinesia + rigidity/tremor)
Three additional categories:
1. Supportive criteria (increase diagnostic confidence)
2. Absolute exclusion criteria
3. Red flags (must be counterbalanced by supportive criteria)
Two certainty levels: Clinically Established PD and Clinically Probable PD

Supportive Criteria for PD (Harrison's)

Clear beneficial response to dopaminergic therapy
Rest tremor
Anosmia
Cardiac sympathetic denervation on MIBG scintigraphy

Red Flags (suggest atypical parkinsonism):

Early postural instability or falls (within first 3 years)
Early dementia (within first 1 year = DLB)
Absence of rest tremor
Symmetrical onset
Poor or no response to adequate levodopa trial
Early prominent autonomic failure
Supranuclear gaze palsy (downward gaze palsy → PSP)
Cerebellar signs
Pyramidal signs

Investigations

DaT PET/SPECT:

Shows reduced and asymmetric striatal dopamine transporter uptake
Most affected: posterior putamen (with relative sparing of caudate)
Does NOT reliably distinguish PD from atypical parkinsonism (both show reduced DaT)

FDG-PET (basal ganglia metabolic imaging):

PD: decreased GPI activity + increased thalamic activity
Atypical parkinsonism: reverse pattern

MRI: Typically normal in idiopathic PD; used to exclude structural causes

Biomarkers (Harrison's 22e - cutting edge):

Alpha-synuclein seed amplification assay (SAA) — detects misfolded alpha-syn in CSF/skin/olfactory epithelium; highly sensitive and specific; increasingly used for early/premotor diagnosis

6. DIFFERENTIAL DIAGNOSIS

Classification of Parkinsonism (TABLE 446-2 — Harrison's)

Category	Examples
PD	Sporadic; Genetic; PD with dementia/DLB
Atypical parkinsonism	MSA (MSA-p, MSA-c); PSP (parkinsonian form, Richardson form); Corticobasal syndrome (CBS)
Secondary parkinsonism	Drug-induced; Vascular; Tumor; Infection; NPH; Toxins (MPTP, CO, manganese)
Other neurodegenerative	Wilson's disease; Huntington's (Westphal variant); Spinocerebellar ataxias; PANK-associated neurodegeneration

Key Distinguishing Features

Diagnosis	Key Clue
Drug-induced	Neuroleptics, metoclopramide, flunarizine, cinnarizine, amiodarone, lithium, tetrabenazine
MSA	Parkinsonism + cerebellar signs + severe autonomic failure; alpha-syn in oligodendrocytes (GCIs); MRI: putaminal rim / hot cross bun sign
PSP	Early falls + downward gaze palsy + eyelid apraxia; tau pathology; MRI: hummingbird sign (midbrain atrophy)
CBS	Alien limb, apraxia, cortical sensory loss; asymmetric
DLB	Dementia develops before or within 12 months of parkinsonism; core: fluctuating cognition + recurrent visual hallucinations + RBD; GBA1 a major risk
Wilson's disease	Age <40; liver disease; Kayser-Fleischer rings; MUST exclude — treatable
DRD	Age <20; levodopa-responsive; no fluorodopa PET abnormality; no drug-induced dyskinesias; GTP-CH1 mutation

7. TREATMENT

A. LEVODOPA — The Gold Standard

"Levodopa remains the most effective symptomatic treatment for PD and the gold standard against which new therapies are compared." — Harrison's 22e

History: Carlsson (1950s) → reserpine blocks dopamine → parkinsonism → reversed by levodopa. Hornykiewicz → striatal dopamine deficiency in PD → basis of replacement therapy.

Mechanism: Levodopa (DA precursor) crosses BBB → converted to dopamine in surviving SNc neurons → restores striatal DA.

Always combined with peripheral decarboxylase inhibitor:

Carbidopa (USA) — brand: Sinemet
Benserazide (Europe) — brand: Madopar
Purpose: block peripheral levodopa conversion → prevent nausea, vomiting, orthostatic hypotension (from area postrema dopamine receptors that lie outside the BBB)

Available formulations (Harrison's 22e):

Formulation	Example
Standard oral	Sinemet (carbidopa/levodopa)
Controlled-release	Sinemet CR / Madopar HP
Combined with COMT inhibitor	Stalevo (levodopa + carbidopa + entacapone)
Long-acting oral	Rytary
Intestinal gel infusion (continuous)	Levodopa-carbidopa intestinal gel
Subcutaneous continuous infusion	Available
Inhaled (pulmonary alveoli)	Inbrija — on-demand for off periods

Motor Complications of Chronic Levodopa

Occur in most patients with ongoing disease progression:

Wearing-off effect
- Duration of benefit per dose shortens progressively
- Initial "long-duration response" (hours/days) → eventually approaches drug half-life (60-90 min)
- Due to loss of dopaminergic storage capacity as neurons degenerate
On-off phenomenon
- Rapid, unpredictable switches: "on" (drug working) ↔ "off" (parkinsonism returns)
- Patients may remain in "off" state for hours despite a levodopa dose
Dyskinesias
- Involuntary choreiform/dystonic movements
- Typically at peak dose (peak-dose dyskinesias)

On-demand therapies for off periods (3 FDA-approved):

Inhaled levodopa (Inbrija) — fastest acting
Subcutaneous apomorphine injection (Apokyn)
Sublingual apomorphine (Kynmobi)

B. MAO-B INHIBITORS

Drug	Notes
Selegiline	First-line option; DATATOP study: delayed need for levodopa
Rasagiline	ADAGIO study: 1 mg/d showed disease-modifying consistent benefit (delayed-start design); 2 mg dose failed (reason unclear)

Mechanism of neuroprotection rationale: MAO-B inhibitors block oxidative conversion of MPTP → MPP+; also reduce dopamine oxidative metabolism; propargyl ring provides antiapoptotic effects in lab models.

C. DOPAMINE AGONISTS

Drug	Type	Notes
Pramipexole	Non-ergot	Preferred; also helps depression
Ropinirole	Non-ergot	Preferred
Rotigotine	Non-ergot (patch)	Transdermal delivery
Apomorphine	Non-ergot (SC/SL)	On-demand rescue for off periods
Bromocriptine	Ergot	Less used now

Advantages over levodopa:

Longer duration of action
Lower risk of dyskinesias
Used as initial monotherapy in younger patients to delay dyskinesias

Important adverse effects: Nausea, orthostatic hypotension, somnolence (sudden sleep attacks — important for driving), hallucinations, impulse control disorders (gambling, hypersexuality, binge eating — particularly with pramipexole/ropinirole)

D. COMT INHIBITORS

Drug	Notes
Entacapone	Preferred; no hepatotoxicity; multiple daily dosing
Opicapone	Once daily; no hepatotoxicity; taken on empty stomach
Tolcapone	Risk of fulminant hepatic necrosis → reserved for refractory cases only; requires liver function monitoring

Mechanism: Block COMT → reduce levodopa conversion to 3-O-methyldopa (which competes with levodopa for CNS transport) → increase brain dopamine → reduce wearing-off

E. AMANTADINE

NMDA glutamate receptor antagonist (also mild dopaminergic + anticholinergic)
Uses: mild early PD symptoms; crucially — treatment of levodopa-induced dyskinesias in advanced PD

F. ANTICHOLINERGICS

Benztropine, trihexyphenidyl
Primarily for tremor in younger patients
Avoid in elderly — anticholinergic burden (confusion, memory impairment, urinary retention, constipation)

G. NEUROPROTECTION (Major unmet need — Harrison's 22e)

"A neuroprotective or disease-modifying therapy that slows or stops disease progression remains the major unmet therapeutic need."

Current investigational targets:

Anti-alpha-synuclein therapies (prevent aggregation/accumulation)
LRRK2 inhibitors
GBA1/GCase enhancers
GLP-1 agonists (anti-inflammatory, pro-mitochondrial) — results in double-blind trials have been inconsistent

H. SURGICAL TREATMENT

Historical evolution (Harrison's):

Motor cortex lesions → improved tremor but caused motor deficits → abandoned
VIM thalamotomy → reduced tremor, no hemiparesis, but no benefit for bradykinesia/rigidity
Posteroventral pallidotomy (GPi lesion) → improved rigidity, bradykinesia, tremor + markedly reduced dyskinesias; but bilateral lesions → dysphagia, dysarthria, cognitive impairment
STN lesions → anti-parkinsonian + reduced levodopa need, but risk of hemiballismus

Deep Brain Stimulation (DBS) — Current standard:

Electrode implanted into target → connected to subcutaneous stimulator over chest wall
Disrupts pathological neurophysiological signals without making a brain lesion
Fully reversible and adjustable (voltage, frequency, pulse duration, electrode configuration)
Suitable for bilateral procedures safely

DBS targets:

Target	Best for
STN (subthalamic nucleus)	All cardinal features; allows levodopa dose reduction
GPi (globus pallidus interna)	All cardinal features + especially dyskinesias; less risk of depression vs STN
VIM thalamus	Tremor only

Indications for DBS:

Severe tremor refractory to medications
Motor fluctuations / dyskinesias not controlled by drug adjustments
Good cognitive function
Good levodopa response (except for tremor)

DBS side effects:

Surgical: hemorrhage, infarction, infection
Hardware: lead displacement, lead break, skin ulceration
Stimulation: ocular/speech abnormalities, paresthesias, depression, rarely suicidality

DBS does NOT prevent nondopaminergic progression (freezing, falls, dementia continue to evolve).

Focused Ultrasound (FUS) Thalamotomy: Non-invasive; approved for tremor-predominant PD.

8. MANAGEMENT OF NONMOTOR FEATURES (Harrison's 22e)

Harrison's explicitly states: "Nondopaminergic features (especially falls and dementia) are the primary source of disability and main reason for hospitalization and nursing home placement in the levodopa era."

Problem	Management
Depression (~50%)	Pramipexole (also helps motor features); SSRIs; tricyclics; don't withhold in major depression
Anxiety	Better dopaminergic control; short-acting benzodiazepines
Psychosis	Step-down: stop anticholinergics → stop amantadine → stop DA agonists → reduce levodopa → add atypical antipsychotic
Atypical antipsychotics	Clozapine (effective but needs CBC monitoring for agranulocytosis); Quetiapine (used but not proven in RCTs); Pimavanserin (5-HT2A inverse agonist; no motor worsening; mild efficacy; QT prolongation risk)
Dementia (PDD)	Rivastigmine (ChEI — approved for PDD); ultimately affects up to 80%
REM Sleep Behaviour Disorder	Clonazepam 0.5-1 mg at bedtime; melatonin; polysomnography if needed
Constipation	Osmotic laxatives, fibre, hydration; correlates with disease severity
Orthostatic hypotension	Fludrocortisone, midodrine, droxidopa, compression stockings
Sialorrhoea	Botulinum toxin injections into salivary glands
Freezing	Sensory cues (marching in place, stepping over imaginary line, counting); "on" period freezing has no specific treatment
Excess daytime sleepiness	Sodium oxybate (Xyrem) being evaluated; patient counselling re: driving

Light therapy (Harrison's 22e — new): Exposure to specific light frequencies restores normal circadian rhythm (altered in PD) → both motor and nonmotor benefits, especially sleep and mood.

9. CURRENT MANAGEMENT ALGORITHM (Harrison's 22e)

DIAGNOSIS OF PD
      |
      ├── No functional disability → MAO-B inhibitor (rasagiline/selegiline)
      |                              [potential neuroprotection + mild symptom relief]
      |
      ├── Functional disability present:
      |         |
      |         ├── Age <60 / Cognitively intact → DA AGONIST first
      |         |   (delays dyskinesias; longer duration of action)
      |         |
      |         └── Age >70 / Cognitively impaired → LEVODOPA first
      |             (most effective; agonists poorly tolerated in elderly)
      |
      ├── Motor complications develop (wearing-off/dyskinesias):
      |         → Adjust levodopa dosing/intervals
      |         → Add COMT inhibitor (entacapone/opicapone) for wearing-off
      |         → Add amantadine for dyskinesias
      |         → On-demand therapies for off periods (inhaled levodopa, apomorphine)
      |
      └── Refractory motor complications → Consider DBS (STN or GPi)

Key principle from Harrison's: Striatal dopamine terminal degeneration may be complete within 4 years of diagnosis — limiting potential benefit of neuroprotective therapy started late.

10. PROGNOSIS

Progression typically over 5-15+ years
Nondopaminergic features (dementia, falls, autonomic failure) cause the most late disability
Dementia ultimately affects up to 80% of patients
Leading cause of death: aspiration pneumonia; complications of immobility; falls

11. KEY EXAM FACTS AT A GLANCE

Point	Fact
Pathological hallmark	Lewy bodies (alpha-synuclein) in SNc
Most common genetic form	LRRK2 (AD)
Most common AR form	PRKN/Parkin
Most common genetic risk factor	GBA1 (heterozygous)
Drug that causes parkinsonism + watch for	Metoclopramide (a neuroleptic used for GI)
Must always rule out in young-onset	Wilson's disease (treatable!)
Gold standard treatment	Levodopa
Most effective for dyskinesias	Amantadine; GPi-DBS
Antipsychotic that doesn't worsen parkinsonism	Pimavanserin (5-HT2A inverse agonist)
RBD treatment	Clonazepam 0.5-1 mg at bedtime
DBS preferred for dyskinesias	GPi (less depression risk vs STN)
Primary disability cause in levodopa era	Falls + dementia (nondopaminergic)
Premotor markers	Anosmia, constipation, RBD
Alpha-synuclein prion evidence	Lewy bodies found in transplanted fetal neurons from PD patients

Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025), Chapter 446: Parkinson's Disease and Related Disorders — C. Warren Olanow, Anthony H.V. Schapira, Christine Klein.

This is a shared conversation. Sign in to Orris to start your own chat.